Consistent Improper Use of Dry Powder Inhalers
9/1/16 A study of 54,354 inhaler user from 1975 to 2014 shows 31% of patients with asthma or COPD use their inhalers correctly, 41% had acceptable use and 31 % had poor use technique. The inability to use the inhalers correctly came from bad coordination, incorrect preparation, speed and/or depth of inspiration and post inhalation breath hold. This poor technique continues to be a major issue among both patients and health care professionals. Correcting this issue is key in combating lung related diseases. The data suggests that there remains an unmet need for simpler, easier to use inhaler devices.
That is where the DoseOne™ Single Dose Powder Inhaler comes in! This patented inhaler (US Patent #7,832,399 B2 & 8,360,057 B2) is a single use disposable dry powder inhaler that is:
– Vaccine-ready
– Easy to Carry & package for epidemic/pandemic necessity
– Fills a unique niche in the dry powder inhaler market
– Achieves new demanding regulatory requirements previously only achievable using complicated device designs such as:
• Dose counting
• Powder holdup
• Dose readiness indication
• Dose completion / user feedback
DoseOne™ is extremely easy to use and requires minimal training. The device, as currently designed, requires three steps to use:
• Removal from over-pack
• Actuation
• Inspiration
Actuation is a simple compressive snap and as a result of it’s simple operation, DoseOne™ has an excellent application in the delivery of drugs (such as vaccinations) to third-world countries.
This DPI is pilot-production ready and ripe for an active partner to bring it to market. It is already prototyped, tested, recently benchmarked, and ready for pilot production and a partner to move it forward. It can be tested in pilot production immediately because it is already designed, molded, and ready for slight modifications to fit a particular size molecule.
If you are interested in this product, please email DBibber@Dose-One.com for more details.